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Critical limb ischemia (CLI) represents the most severe form of peripheral arterial disease
(PAD) and frequently occurs in medically frail patients. CLI patients frequently exhibit multi-
segmental PAD commonly including the tibial arterial segment. Endovascular therapy has
been established as first-line revascularization strategy for most CLI patients. Restenosis
was reported to occur in up to more than two-thirds of CLI patients undergoing angio-
plasty of complex tibial arterial obstructions. Nevertheless, favorable clinical outcomes
were observed for infrapopliteal angioplasty when compared with bypass surgery, despite
higher patency rates for the latter. Based on these observations, infrapopliteal patency was
considered to be only of secondary importance upon clinical outcomes in CLI patients.
In contrast to these earlier observations, however, recent findings from two randomized
clinical trials indicate that infrapopliteal patency does impact on clinical outcomes in CLI
patients. The purpose of the present manuscript is to provide a critical reappraisal of the
present literature on the clinical importance of tibial arterial patency in CLI patients undergo-
ing endovascular revascularization and to discuss utility and limitations of currently available
anti-restenosis technologies.
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INTRODUCTION
Critical limb ischemia (CLI) represents a medically frail subgroup
of patients presenting with the most severe form of peripheral
arterial disease (PAD) (1–3). In these patients, revascularization is
among the cornerstones of treatment and aims at the prevention
of amputation and improvement of quality of life (1, 4, 5). CLI
patients frequently present with multilevel PAD including com-
plex obstructions of tibial arteries and, thus, frequently require
challenging revascularization procedures. Endovascular therapy
has been established as a first-line revascularization strategy for
most CLI patients (5, 6) since it was shown to provide com-
parable clinical outcomes when compared with bypass surgery,
despite higher patency rates for the latter (5, 7). Based on these
observations, the tide over concept was established assuming that
tibial arterial patency was mandatory only during the process of
wound healing but not thereafter for the maintenance of skin
integrity and resolution of CLI symptoms (7–9). More recent stud-
ies, however, have stressed the importance of tibial patency upon
clinical outcomes in CLI patients, thereby challenging the tide over
concept (10–13).
The purpose of this review article is to provide a critical reap-
praisal of the importance of tibial arterial patency on clinical
outcomes in CLI patients. Moreover, we seek to analyze recently
performed trials on endovascular revascularization for tibial PAD
and to stress their applicability to everyday clinical practice.
METHODS
A comprehensive literature research was performed based on
Pubmed database. All studies included in the meta-analysis by
Romiti et al. (7) were acquired using Pubmed and analyzed there-
after (researched April 2013). In addition, we reviewed literature
for completed and ongoing randomized trials on drug-eluting
stents (DESs) and drug-eluting balloon (DEB) versus bare metal
stent (BMS) and/or plain-old balloon angioplasty (POBA) for tib-
ial arterial revascularization. The latter literature research was
based on Pubmed (www.pubmed.org, last accessed on March
13, 2014) and clinicaltrials.gov (last accessed on April 28, 2014)
entries.
INCIDENCE OF TIBIAL ARTERIAL RESTENOSIS AFTER
ANGIOPLASTY
Restenosis remains the major drawback in CLI patients undergo-
ing endovascular therapy of tibial arterial obstructions. Various
studies reported tibial restenosis to occur in up to more than two-
thirds of patients undergoing angioplasty of complex tibial arterial
obstructions (10–12, 14, 15). Within a prospective study, Schmidt
and colleagues evaluated the incidence of tibial arterial resteno-
sis in CLI patients undergoing POBA. Restenosis was defined as a
lumen compromise≥ 50% on serial angiography after 3 months
(15). A total of 58 CLI patients (77 limbs) with a mean tibial
lesion length of 184 mm were analyzed. In that cohort, binary
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restenosis was observed in 68.8% of limbs. Similar results were
observed by Liistro and coworkers within the DEBATE-BTK trial
(10) comparing POBA versus DEB. In that study, binary restenosis
was assessed by angiography and defined as a reduction of luminal
diameter> 50% or by duplex sonography defined as a peak systolic
velocity index≥ 2.5. After 1 year, tibial restenosis was observed in
74% in the POBA (74 limbs, mean lesion length: 131 mm) and
27% in the DEB group (74 limbs, mean lesion length: 129 mm
[P < 0.001]). In addition, Iida and coworkers analyzed the inci-
dence of tibial restenosis and its impact on clinical outcomes in
CLI patients after POBA in a total of 63 patients (12). Restenosis
was evaluated angiographically and defined as a reduction of lumi-
nal diameter≥ 50%. After 3 months, tibial restenosis was observed
in 74/102 (73%) of treated lesions. Of note, no detailed informa-
tion on tibial lesion length was provided in that study, although
tibial lesion length was shown to be indicative for the risk of tibial
restenosis (16).
IMPACT OF TIBIAL ARTERIAL PATENCY ON CLINICAL
OUTCOMES IN CLI
Despite the high rates of tibial restenosis subsequent to POBA,
endovascular revascularization is considered the first-line treat-
ment strategy for most CLI patients (5, 6). Until now, the BASIL
trial was the first and only trial randomly comparing endovascular
therapy with open surgery in CLI patients undergoing infrain-
guinal revascularization (5). In that trial, a total of 452 patients
(224 angioplasty, 228 surgery) were analyzed for amputation-free
survival. After 1 year, an amputation-free survival was obtained in
68 versus 71% and after 3 years 57 versus 53% comparing bypass
surgery with angioplasty (P > 0.05). This observation was under-
lined by a frequently cited meta-analysis by Romiti et al. (7). In
that meta-analysis, the impact of tibial patency on clinical out-
comes comparing endovascular versus surgical revascularization
strategies in CLI was scrutinized. For that reason, a total of 30
studies including 2646 patients were analyzed (Table 1). Primary
patency was 58.1, 51.3, and 48.6% after tibial angioplasty and 81.5,
76.8, and 72.3% after tibial bypass surgery at 12, 24, and 36 months
(P < 0.05). Of interest, despite these significant differences in
patency rates, no significant differences in clinical outcomes were
observed: limb salvage rates were 86.0, 83.8, and 82.4% in patients
treated by angioplasty and 88.5, 85.2, and 82.3% after tibial bypass
surgery at same intervals. Based on these findings, the tide over
concept was established assuming that increased perfusion was
mandatory for ulcer healing in CLI but not thereafter for maintain-
ing skin integrity. Therefore, tibial arterial patency was considered
to be of minor importance during mid- and long-term follow-up
of CLI patients.
For several reasons, however, the validity of the methodological
design and conclusion of that meta-analysis must be consid-
ered as limited. First, the sample size in the majority of stud-
ies included was small and ranged from 23 to 537 patients. Of
note, 16/30 (53.3%) studies had included less than 50 patients.
In addition, 9/30 (30%) studies included both CLI and patients
with intermittent claudication. Thus, a substantial fraction of the
patients (548/2646, 20.7%) did not suffer from limb-threatening
ischemia. Accordingly, statistical power of both individual studies
and the meta-analysis was limited. Second, a direct comparison of
functional clinical outcomes is limited due to substantial variabil-
ity of clinical end point definitions or the lack of clinical outcome
reports at all (20, 33). Clinical end point definitions included sub-
jective relief, freedom from CLI, improvement of clinical classifica-
tion, and limb salvage (8, 32, 40, 41). Moreover, clinical outcomes
were not reported throughout all studies but only in 26/30 (86.7%)
studies. Third, systematic patency evaluation was performed in
only 9/30 (30%) of studies included within the meta-analysis (17–
19, 24, 33, 37, 38, 44, 45). Remarkably, patency was assessed by
duplex sonography in 8/30 (26.7%) studies and by angiography in
only 1 (3.3%) study in a total of 60/2646 (2.3%) patients. Thus,
the vast majority of patency evaluation was performed by duplex
sonography, although its validity in tibial arteries is highly contro-
versial (42). In addition, information on tibial patency was derived
from the clinical need for repeated intervention in 4/30 (13.3%)
studies. Thus, arterial patency rates may have been overestimated
utilizing this surrogate definition. Fourth, Romiti et al. published
3-year outcomes, although only 16/30 (53.3%) studies reported
follow-up results beyond 24 months.
In addition to these limitations, the importance of tibial patency
upon clinical outcomes was recently endorsed by various studies
(10–13). It was shown that CLI patients require frequently tar-
get lesion revascularization (TLR) to maintain favorable clinical
results subsequent to tibial angioplasty. Within the aforemen-
tioned study by Iida, TLR was necessary in 48% of patients
with documented restenosis of the tibial target lesion in 73% at
12-month follow-up. In addition, the authors observed a pro-
longed time of wound healing in patients with tibial resteno-
sis when compared to patients without restenosis: 127 versus
66 days (P = 0.02). The high prevalence of tibial TLR was recently
corroborated by Baumann et al. within a consecutive series of
128 CLI patients undergoing tibial angioplasty (13). That group
aimed for a comparison analyzing the clinically driven need for
TLR versus target extremity revascularization (TER) after tib-
ial angioplasty. After 1 year, TLR was performed in 41.6% and
TER in 17.2% of patients. While adding proof to the high preva-
lence of TLR after tibial angioplasty, that observation more-
over indicated that tibial restenosis is of greater clinical impact
than progression of atherosclerotic disease as reflected by TER
rates.
Moreover, Rastan et al. were the first to underline the impor-
tance of tibial patency within a randomized setting (11). The
Yukon BTK trial randomly assigned a total of 161 patients compar-
ing DES (82 patients) to BMS (79 patients) for tibial angioplasty
in CLI. Primary clinical end point in the Yukon BTK trial was an
event-free survival defined as freedom from target limb ampu-
tation, target vessel revascularization, myocardial infarction, and
death. After a follow-up period of 1016 days, an event-free sur-
vival was attained in 65.8% in the DES group versus in 44.6% in
the BMS group (P = 0.02). In line with clinical observations, pri-
mary tibial patency at 1 year was 80.6 versus 55.6% (P = 0.004)
when comparing DES with BMS (46).
Thus, in consideration of these substantial limitations behind
the tide over concept and given observations from more recent
clinical trials (11–13), the ultimate importance of tibial arter-
ial patency subsequent to endovascular therapy remains to be
determined.
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Table 1 | Summary of all studies analyzed within the meta-analysis of Romiti and coworkers.
Ref. Patients (n) Limbs (n) s/e Patency evaluation
(specifications)
End points Reported fu
(months)
Mean fu
(months)
Haider et al. (17) 32 32 e DUS PP: 60% 24 n.i.
Kudo et al. (18) 52 52 e DUS/ABI PP: 23.5%, SP: 46.1%, LS:
77.3%
36 14.7
Boyer et al. (19) 49 49 e DUS PP: 81%, SP: 88%, LS: 87% 36 21
Parsons et al. (20) 66 66 e ABI/pulse volume recordings PP:<15% 12 n.i.
Spinosa et al. (21) 37 37 e ABI/pulse volume recordings LS: 66% 12 7.8
No info on patency
Wölfle et al. (22) s:125 130, IC: 3,
CLI: 127
s/e CI/ABI (DUS after 1991) PPs: 46%, SPs: 49%, LSs:
63%
84 (s) n.i.
e:84 89, IC: 5,
CLI: 84
LSe: 63%, e: no patency
information
72 (e) n.i.
Marzelle et al. (23) 23 23 e Clinical PP: 34%, LS: 71% 12 8.6
Vraux et al. (24) 36 40 e DUS PP: 56%, SP: 72%, LS: 81% 12 10
Treiman et al. (25) 25, IC: 5,
CLI: 20
25 e CI: ABI, DUS/angiography, (if
ABI-impair>0.1 or clinical
deterioration)
CI: 59% (32%, 20%) 12 (24, 36) 44
Brosi et al. (26) 29 38, IC: 13,
CLI: 25
e ABI/clinical LS: 73% 12 5.9
Aulivola et al. (27) 79 90 e n.i. LS: 84.4% (52.5%)
non-ESRD, LS: 80.2%
(52.5%) ESRD
(12, 36) 14.3
Sigala et al. (28) 50 50 e Clinical LS: 68.9% 24 15
Brillu et al. (29) 37 37 e Clinical LS: 87% 24 28
Brown et al. (30) 40 55 e CI CI: 44% 25.8 25.8
Bull et al. (31) 168, IC: 40,
CLI: 128
168 e CI CI: 83% (single stenosis), CI:
76% (multilevel lesions), CI:
44% (lytic therapy), CI: 36%
(segmental occlusion)
36 26.1
Danielsson et al. (32) 140 155, IC: 16,
CLI: 139
e CI (improvement of subjective
relief)
CI: 66% (non-DM) CI: 32%
(DM), LS: 66% (non-DM), LS:
90% (DM)
12 n.i.
Favre et al. (33) 24, IC: 4,
CLI: 20
25 e DUS PP: 46%, SP: 64% 24 15
Löfberg et al. (34) 82 86 e CP (according to SVS/ISCVS
standards)
CP: 36%, LS: 72% 36, 36 n.i.
Ingle et al. (35) 67, IC: 6,
CLI: 61
70 e CP (freedom from CLI) CP: 84%, LS: 94%, 36 n.i.
Vraux et al. (24) 46 50 e Intention to treat CP PP: 46%, SP: 55%, CP: 63%,
LS: 87%
12 15
Nydahl et al. (36) 27, IC: 4,
CLI: 24
28 e CP (symptomatic patency) CP: 56%, LS: 85%, survival:
81%
12 n.i.
(Continued)
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Table 1 | Continued
Ref. Patients (n) Limbs (n) s/e Patency evaluation
(specifications)
End points Reported fu
(months)
Mean fu
(months)
Tisi et al. (37) 57 57 e DUS: n=26, Angiography:
n=3 (angiography if
ABI-impair>0.1 or clinical
deterioration)
PP: 27%, SP: 33%, LS: 88% 12 n.i.
Söder et al. (38) 60 72 e Angiography PP: 48%, SP: 56%, LS 80% 18 10
Barton et al. (39) 43 n.i. e CI (asymptomatic) CI: 60% 36 28
Lazaris et al. (40) 24 24 e Intention to treat PP: 50%, LS: 92% 12 n.i.
Sivananthan et al. (41) 38, IC: 18,
CLI: 20
41 e CI: (improvement≥1
Fontaine category)
CI: 58% at last fu 21
Faglia et al. (8) 537, s: 117,
e: 420
537 s/e CP (no recurrence of
pain/ulcer)
CP, PTA: 78%, Bypass: 77% 60 40
Bosiers et al. (42) 443 443 e DUS PP: 74.2%, LS: 96.6% 12, 12 n.i.
Schwarten (43) 96 112 e n.i. LS: 83% 24 n.i.
Ascher et al. (44) 30 32, IC: 12,
CLI: 20
e DUS LS: 100%, PP: 85% 3 5.2
Table 2 | Overview of randomized series comparing BMS with POBA for tibial revascularization in CLI patients.
Ref. No. patients/
lesions
Lesion length
(mm)
Follow-up Patency evaluation
(number)
Patency (%) Clinical
end points (%)
COMPLETED RANDOMIZEDTRIALS ON BMS FOR BTK
Rand et al. (49) 51/95 24 6 months Angiography: 18 BMS: 79.7 LS
BMSa: 42 BMS: 9 PTA 45.6 (P =0.02) BMS: 92
PTA: 53 PTA: 9 PTA: 95 (P =ns)
CT-Angio: 19
BMS: 8
PTA: 11
Randon et al. (50) 35/38 BMS: 22 12 months Clinical patency BMS: 66.0 LS
BMSb: 16 PTA: 39 PTA: 79.5 (P =ni) BMS 92.7
PTA: 22 PTA: 90.0 (P =0.76)
Brodmann et al. (48) 54/54 BMS: 28 12 months BMS: 35.3 CI
BMSa: 21 PTA: 79 PTA: 41.8 (P =ns) BMS: 64.7
PTA: 33 PTA: 81.5 (P =ns)
PLANNED OR ONGOING RANDOMIZEDTRIALS ON BMS FOR BTK ANGIOPLASTY
XXSc 180 <150 12 Angiography – TLR
BMS, bare metal stent; BTK, below the knee; No., number; PTA, percutaneous angioplasty; ns, not significant; ni, no information; LS, limb salvage; CI, clinical
improvement (improvement≥1 category according to Rutherford classification); P, P value; TLR, target lesion revascularization.
aBalloon-expandable BMS.
bIncluding balloon-expandable and self-expandable BMS.
cSelf-expandable BMS.
CURRENTLY AVAILABLE TECHNOLOGIES AIMED AT THE
PREVENTION OF RESTENOSIS
Given the excessive incidence of tibial arterial restenosis (10, 12,
14, 15) subsequent to POBA, various endovascular technologies
have been assessed in the framework of clinical trials.
BARE METAL STENTS
Mechanical scaffolding as provided by a stent may be an ideal
solution to address elastic recoil, an important contributor to
restenosis in tibial arteries (47). The application of tibial BMS
was assessed in various studies (48–50). However, no substantial
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benefit of BMS application when compared with POBA was
observed within three randomized trials (48–50) (Table 2). Based
on these observations, it may be assumed that neointimal pro-
liferation induced by BMS outweighs the potential benefit of
mechanical scaffolding in the prevention of restenosis induced
by elastic recoil.
DRUG-ELUTING STENTS
Given the above-outlined drawbacks of BMS in tibial interven-
tions, great hope was attributed to DES technology. The principle
of DES is to provide mechanical scaffolding but with a minimum
of neointimal proliferation based on the antiproliferative coating.
Four randomized trials compared DES versus POBA or BMS for
tibial angioplasty (46, 51–53) (Table 3). Whilst the Yukon trial
compared DES with BMS (46), the remaining randomized studies
compared DES to POBA (51–53). Without exception, DES was
superior when compared with BMS/POBA for tibial angioplasty
in respect to patency and the need for repeated TLR. In addi-
tion, DES was shown to improve event-free survival rates when
compared with BMS as shown within the aforementioned Yukon
trial (11).
Of note, however, tibial arterial lesion lengths of patients
included in all randomized DES trials were ≤35 mm. Within a
consecutive series, Baumann et al. analyzed tibial lesion mor-
phology in 105 CLI patients undergoing tibial angioplasty (16).
Thereby, a mean lesion length of 87 mm was observed for stenotic
and 124 mm for occlusive tibial PAD. According to these mor-
phological findings, only 11% of that study population would
have qualified for participation within the above-mentioned ran-
domized DES trials. Thus, currently available coronary DES is
applicable to only a minority of CLI patients treated in everyday
clinical practice.
Table 3 | Overview of randomized trials comparing DES versus BMS or POBA for BTK angioplasty.
Reference Devices Rutherford
categories
Renal
insufficiency
Inclusion
criteria
Patients
(n)
Follow-up
(months)
Final LL End point Results
Yukon (46) DES° versus
BMS (° Yukon,
Translumina,
Hechingen,
Germany)
2–5 n.i. de novo
lesions steno-
sis>70%,
LL<45 mm
161 12 31±9 Restenosis
(>50%)
(a) DUS
(PSVR>2.4)
Primary
patency
DES: 80.6%
BMS: 55.6%
(P =0.004)
Secondary
patency
(b) Angiography DES: 91.9%
BMS: 71.4%
(P :0.005)
Destiny
(52)
DES° versus BMS
(° Xience V stent)
4, 5 n.i. de novo steno-
sis>50%,
LL<40 mm
140 12 n.i. Restenosis>
50% by
angiography
Primary
patency
DES: 85%
BMS: 54%
(P =0.0001)
Falkowski
(53)
DES° versus BMS
(° Cipher Cordis
Europa N.V.)
3–5 n.i. de novo steno-
sis>60%, LL
5–30 mm
50 6 17.8 PE: Resteno-
sis>50% by
angiography
Primary
patency
DES: 16%
BMS: 76%
(P =0.001)
SE: TLR TLR
DES: 12%
BMS: 56%
(P <0.05)
RANDOMIZEDTRIALS ON DES VERSUS POBA FOR BTK ANGIOPLASTY
Achilles
(51)
DES° versus
POBA (° Cipher
Select, Cordis
Cooperation,
USA)
3–5 exclusion:
creatinine>
2.5 mg/dl
de novo and
restenotic
native steno-
sis>70%,
LL<120 mm
200 (99
versus
101)
12 27±21 Restenosis by
angiography
Primary
patency
DES: 77.6%
POBA: 58.1%
n, number; n.i., no information; LL, lesion length; DUS, duplex ultrasound; PSVR, peak systolic velocity ratio; DES, drug-eluting stent; BMS, bare metal stent; TLR,
target lesion revascularization; PE, primary end point; SE, secondary end point; POBA, plain-old balloon angioplasty.
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Table 4 | Overview of ongoing/not completed randomized trials on DEB versus BMS or POBA for BTK angioplasty.
Study name Devices Rutherford
categories
Predefined
LL (mm)
Patients
(n)
Follow-up
(months)
End points
PLANNED/ONGOING RANDOMIZEDTRIALS ON DEB FOR BTK ANGIOPLASTY
IDEAS-I DEB versus BMS 3–6 70–220 50 6 Restenosis (angiography)
Piccolo DEB versus POBA 3–5 15–150 114 6 Late lumen loss (angiography)
InPact Deepa DEB versus POBA 4–6 <100 450 12 Clinically driven TLR,
restenosis (angiography)
Euro Canalb DEB versus POBA 4–6 10–270 120 6 Late lumen loss (angiography)
DEB, drug-eluting balloon; BMS, bare metal stent; POBA, plain-old balloon angioplasty; BTK, below the knee; LL, lesion length; n, number; TLR, target lesion
revascularization; DUS, duplex ultrasound.
aStudy terminated early based on safety concerns.
bStudy terminated early based on strategic company decision, no safety concerns.
DRUG-ELUTING BALLOONS
DEB technology was introduced with the intention of reducing
neointimal proliferation. First, by limiting the mechanical irri-
tation to the duration of balloon inflation, and second, by the
application of an antiproliferative substance during the endothelial
injury phase induced by angioplasty. According to first obser-
vations, the application of DEB may reduce restenosis and the
need for repeated revascularization when compared with POBA
for tibial revascularization (10, 54).
Within a non-randomized study setting, Schmidt et al. eval-
uated the application of DEB for tibial revascularization in 104
patients (CLI: 82.6%, severe claudication: 17.4%, limbs: n= 109)
(54). Binary restenosis was evaluated using angiography and
defined as a> 50% reduction of lumen diameter. After 3 months,
binary restenosis after DEB was observed in 27.4%. Within a
similar cohort of historic control patients at the same center under-
going tibial POBA, restenosis was reported in 68.8% after 3 months
(54). According to this, DEB was shown to reduce tibial resteno-
sis by around 60% when compared with POBA and, thus, great
hope was placed on DEB technology aimed at improving tibial
patency. The superiority of DEB over POBA in tibial arteries was
furthermore shown by Liistro et al. who were the first to report
results from a randomized trial (10). Within the DEBATE-BTK
trial, Liistro and coworkers analyzed 132 patients for tibial angio-
plasty randomly assigned for 67 DEB and 65 POBA. Mean lesion
length was 129 mm in patients treated with DEB and 131 mm
treated with POBA (P = 0.9). Primary end point in that trial was
binary restenosis defined> 50% after 12 months by angiography
(>90% of patients) and/or duplex sonography for the remain-
ing. Secondary clinical end points were the incidence of TLR and
amputation. Binary restenosis was 27% in the DEB and 74% in
the POBA group (P < 0.001). In addition, the need for secondary
TLR was lower in patients treated with DEB compared to those
treated with POBA (18 versus 43%, P = 0.002).
Of note, for technical reasons, operators within most of the ran-
domized and observational trials including the DEBATE-BTK trial
were not blinded to treatment allocation. This may have influenced
the decision of performing TLR and may serve as an explanation
for the wide range of TLR rates. During 1-year follow-up, ampu-
tation was necessary in one patient in the POBA group and none
in the DEB group (P = 0.9). In the meantime, results from further
randomized trials are awaited (Table 4). Of these, the Euro Canal
trial was terminated early due to strategic reorientation of the com-
pany. A second randomized trial performed was the InPact Deep
trial, which was finished but upon completion the company with-
drew the DEB of investigation from the market. This was based on
the 12-month results with lacking efficacy of DEB and moreover
higher major amputation rates for DEB (8.8%) when compared
to POBA (3.6%, P = 0.08).
CONCLUSION
In contrast to earlier observations,patency appears to affect clinical
outcomes in CLI patients, and thus, remains the major drawback
of tibial arterial angioplasty. DES and DEB were shown to improve
tibial patency but both with specific limitations. Accordingly, cur-
rently applied and evaluated DES for tibial revascularization do
not address infrapopliteal lesion morphology. While DEB technol-
ogy complies well with tibial lesion morphology in CLI patients, it
may not address acute elastic recoil, an important contributor to
tibial restenosis. Further studies assessing anti-restenosis concepts
specifically dedicated to the unique requirements of complex tibial
arterial obstructions are warranted.
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